Anonymous
Guest
Anonymous
Guest
Increased risk of bleeding in stroke patients = just another anti-platelet agent and potentially inferior to ticagrelor. This makes triple anti-platelet therapy even more unlikely than before, highly likely this product won't amount to much = really bad news for us.